title: Open study of pranlukast add-on therapy in intractable partial epilepsy.
abstract: Innovative treatments of epileptic seizures are needed to improve the outcome of epilepsy. We studied the effect of pranlukast on seizure outcome in patients with intractable partial epilepsy. An open study was conducted to evaluate the clinical efficacy of 24-week pranlukast add-on therapy in 50 patients with intractable partial seizures. Serum concentrations of matrix metalloproteinase (MMP)-9 were determined using Biotrak Activity Assay System. Cytokines in cerebrospinal fluid (CSF) were measured by the BioPlex (BioRad) system and soluble TNF receptor1 (sTNFR1) in CSF was measured by the ELISA. Surface markers of lymphocytes in CSF were examined by cell-sorter. Seizure-free rate (SFR) was 13.6%, responder rate (RR) was 47.7%, and aggravation rate (AR) was 18.2% at the 13-24 week period after starting pranlukast. In patients with increased serum MMP-9 before pranlukast therapy (baseline), comparison of paired serum levels showed a significant decrease after pranlukast therapy. Baseline CSF levels of IL-1β and IL-6 were elevated in patients compared with disease controls. Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1β, IL-6, and TNFα), and four showed decreased sTNFR1, after pranlukast treatment, and only a responder had markedly decreased frequency of CD8+ T cells in CSF. Pranlukast reduces seizure frequencies probably by pleiotropic effects including normalization of MMP-9 in sera, reduced leakage of pro-inflammatory cytokines into CNS, and inhibition of extravasation of leucocytes from brain capillaries. Further investigations by double-blind control study and animal models are warranted.
authors.affiliation: National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan. takahashi-ped@umin.ac.jp
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Imai
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ikeda
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kubota
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.forename: Fuminobu
authors.initials: F
authors.lastname: Susa
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D002452:Cell Count; D002648:Child; D002867:Chromones / Q000627:therapeutic use*; D016207:Cytokines / Q000134:cerebrospinal fluid; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000134:cerebrospinal fluid; D012640:Seizures / Q000517:prevention & control; D013601:T-Lymphocytes / Q000502:physiology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D002867:Chromones; D016207:Cytokines; D053583:Interleukin-1beta; D015850:Interleukin-6; D020024:Leukotriene Antagonists; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D020780:Matrix Metalloproteinase 9; C047681:pranlukast